{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:32Z","timestamp":1791976052077,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01570-9","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:18:28Z","timestamp":1760717908000},"page":"1785-1797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exposure\u2013Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct04994288","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qinghua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203\u201334.","journal-title":"Lancet"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"S1070","DOI":"10.4103\/jpbs.jpbs_1759_24","volume":"17","author":"V Vybhavi","year":"2025","unstructured":"Vybhavi V, Bhavsar M, Gusani J, Gohil Y, Paul NK, Garlapati HR, et al. New insights into the pathophysiology of type 2 diabetes: a review article. J Pharm Bioallied Sci. 2025;17:S1070\u20132.","journal-title":"J Pharm Bioallied Sci"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803\u201320.","journal-title":"Lancet"},{"key":"1570_CR4","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15-S33.","DOI":"10.2337\/dc21-S002"},{"key":"1570_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101641","volume":"51","author":"J Chen","year":"2025","unstructured":"Chen J, Me C, Coughlan M. Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists. Diabetes Metab. 2025;51: 101641.","journal-title":"Diabetes Metab"},{"key":"1570_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","volume":"3","author":"FM Gribble","year":"2021","unstructured":"Gribble FM, Reimann F. Metabolic messengers: glucagon-like peptide 1. Nat Metab. 2021;3:142\u20138.","journal-title":"Nat Metab"},{"key":"1570_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997578","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Mei A, Wei Y, Li C, Qian H, Min X, et al. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022;13: 997578.","journal-title":"Front Immunol"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409\u201339.","journal-title":"Physiol Rev"},{"issue":"Suppl 1","key":"1570_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"1570_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384: e076410.","journal-title":"BMJ"},{"key":"1570_CR11","doi-asserted-by":"crossref","unstructured":"Wu X, He J, Wu J, Liu W, Xu Y, Li Y, et al. Effect of efsubaglutide alfa on the pharmacokinetics of metformin and digoxin in healthy participants. Clin Pharmacokinet 2025.","DOI":"10.1007\/s40262-025-01541-0"},{"key":"1570_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-20-0255","volume":"248","author":"Q Cui","year":"2021","unstructured":"Cui Q, Liao Y, Jiang Y, Huang X, Tao W, Zhou Q, et al. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol. 2021;248:145\u201354.","journal-title":"J Endocrinol"},{"key":"1570_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fphys.2019.00930","volume":"10","author":"L Ren","year":"2019","unstructured":"Ren L, Cui Q, Liu W, Wang L, Liao Y, Feng Y, et al. Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol. 2019;10:930.","journal-title":"Front Physiol"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1111\/dom.16452","volume":"27","author":"Q Wang","year":"2025","unstructured":"Wang Q, Cui Q, Xu Y, Prud\u2019homme GJ, Yang Y, Zhu D, et al. Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: a randomised, dose-escalation phase 1 study. Diabetes Obes Metab. 2025;27:4220\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2337\/db23-757-P","volume":"72","author":"Q Wang","year":"2026","unstructured":"Wang Q, Zhou Y, Wang W, Tong G, Jia W, Li L. Efficacy and safety of supaglutide monotherapy in patients with type 2 diabetes. Diabetes. 2026;72:757.","journal-title":"Diabetes"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2337\/db23-778-P","volume":"72","author":"D Anwar","year":"2026","unstructured":"Anwar D, Bao Y, Zhou Y, Chen S, Zhou J, Li L. Efficacy and safety of Supaglutide as add-on to Metformin in patients with type 2 diabetes. Diabetes. 2026;72:778.","journal-title":"Diabetes"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-025-01475-7","volume":"64","author":"YR Lou","year":"2025","unstructured":"Lou YR, Xu YL, Xiong Y, Deng C, Wang Q. Population pharmacokinetics of Efsubaglutide Alfa in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2025;64:533\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"1570_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2: e50.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1570_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/dom.12639","volume":"18","author":"JP Wilding","year":"2016","unstructured":"Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016;18:491\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1570_CR20","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1111\/dom.13358","volume":"20","author":"K Petri","year":"2018","unstructured":"Petri K, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20:2238\u201345.","journal-title":"Diabetes Obes Metab"},{"key":"1570_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1570_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44:765\u201373.","journal-title":"Diabetes Care"},{"key":"1570_CR23","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Tof\u00e9 Povedano S, P\u00e9rez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168\u201376.","journal-title":"Diabetes Care"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01570-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01570-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:32:41Z","timestamp":1766053961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01570-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01570-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"QW is the founder and actual controller of Innogen Pharmaceutical Co. Ltd. FJ and YX are employees of the company. All the remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"All data are available upon reasonable request. Data will be made available upon reasonable request, subject to the protection of research participants\u2019 privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"YX and LZ drafted the manuscript. YX, YL, and FJ analyzed the data and produced the figures. QW and XS reviewed and edited the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All studies included in this analysis were approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice (ICH-GCP).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The model codes that support the findings of this study are accessible upon reasonable request by contacting the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Written, informed consent was obtained from all participants.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}